These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 23847585)

  • 1. The importance of tau phosphorylation for neurodegenerative diseases.
    Noble W; Hanger DP; Miller CC; Lovestone S
    Front Neurol; 2013; 4():83. PubMed ID: 23847585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of tau phosphorylation in the pathogenesis of Alzheimer's disease.
    Mi K; Johnson GV
    Curr Alzheimer Res; 2006 Dec; 3(5):449-63. PubMed ID: 17168644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glial contributions to neurodegeneration in tauopathies.
    Leyns CEG; Holtzman DM
    Mol Neurodegener; 2017 Jun; 12(1):50. PubMed ID: 28662669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies.
    Giacomini C; Koo CY; Yankova N; Tavares IA; Wray S; Noble W; Hanger DP; Morris JDH
    Acta Neuropathol Commun; 2018 May; 6(1):37. PubMed ID: 29730992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular and molecular modifier pathways in tauopathies: the big picture from screening invertebrate models.
    Hannan SB; Dräger NM; Rasse TM; Voigt A; Jahn TR
    J Neurochem; 2016 Apr; 137(1):12-25. PubMed ID: 26756400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimer's disease and not in other tauopathies.
    Pires G; McElligott S; Drusinsky S; Halliday G; Potier MC; Wisniewski T; Drummond E
    Acta Neuropathol Commun; 2019 Dec; 7(1):195. PubMed ID: 31796108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tau accumulation in the retina promotes early neuronal dysfunction and precedes brain pathology in a mouse model of Alzheimer's disease.
    Chiasseu M; Alarcon-Martinez L; Belforte N; Quintero H; Dotigny F; Destroismaisons L; Vande Velde C; Panayi F; Louis C; Di Polo A
    Mol Neurodegener; 2017 Aug; 12(1):58. PubMed ID: 28774322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
    Navarrete LP; Pérez P; Morales I; Maccioni RB
    Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tau Secretion.
    Ruan Z; Ikezu T
    Adv Exp Med Biol; 2019; 1184():123-134. PubMed ID: 32096034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau phosphorylation in neuronal cell function and dysfunction.
    Johnson GV; Stoothoff WH
    J Cell Sci; 2004 Nov; 117(Pt 24):5721-9. PubMed ID: 15537830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies.
    Caccamo A; Magrì A; Medina DX; Wisely EV; López-Aranda MF; Silva AJ; Oddo S
    Aging Cell; 2013 Jun; 12(3):370-80. PubMed ID: 23425014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease.
    Stancu IC; Ferraiolo M; Terwel D; Dewachter I
    Adv Exp Med Biol; 2019; 1184():145-166. PubMed ID: 32096036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tau phosphorylation: physiological and pathological consequences.
    Stoothoff WH; Johnson GV
    Biochim Biophys Acta; 2005 Jan; 1739(2-3):280-97. PubMed ID: 15615646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of Tau Pathology to Mitochondrial Impairment in Neurodegeneration.
    Pérez MJ; Jara C; Quintanilla RA
    Front Neurosci; 2018; 12():441. PubMed ID: 30026680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tau and Axonal Transport Misregulation in Tauopathies.
    Combs B; Mueller RL; Morfini G; Brady ST; Kanaan NM
    Adv Exp Med Biol; 2019; 1184():81-95. PubMed ID: 32096030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathological conformations involving the amino terminus of tau occur early in Alzheimer's disease and are differentially detected by monoclonal antibodies.
    Combs B; Hamel C; Kanaan NM
    Neurobiol Dis; 2016 Oct; 94():18-31. PubMed ID: 27260838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease.
    Hanger DP; Anderton BH; Noble W
    Trends Mol Med; 2009 Mar; 15(3):112-9. PubMed ID: 19246243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drosophila models of human tauopathies indicate that Tau protein toxicity in vivo is mediated by soluble cytosolic phosphorylated forms of the protein.
    Feuillette S; Miguel L; Frébourg T; Campion D; Lecourtois M
    J Neurochem; 2010 May; 113(4):895-903. PubMed ID: 20193038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing microtubule stabilization rescues cognitive deficits and ameliorates pathological phenotype in an amyloidogenic Alzheimer's disease model.
    Fernandez-Valenzuela JJ; Sanchez-Varo R; Muñoz-Castro C; De Castro V; Sanchez-Mejias E; Navarro V; Jimenez S; Nuñez-Diaz C; Gomez-Arboledas A; Moreno-Gonzalez I; Vizuete M; Davila JC; Vitorica J; Gutierrez A
    Sci Rep; 2020 Sep; 10(1):14776. PubMed ID: 32901091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tauopathies.
    Hernández F; Avila J
    Cell Mol Life Sci; 2007 Sep; 64(17):2219-33. PubMed ID: 17604998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.